Comment by
JMark80 on Jun 02, 2020 7:43pm
RE:Dilution
Dilution is just one reason. When I first researched Nemus in 2015 the number of shares outstanding was ~15mm, and phase 1 for glaucoma was supposed to be conducted in 2017. CEO was replaced with the CMO Brian Murphy, lawsuit followed over wrongful termination but was withdrawn. Brian Murphy announced a fake financing with fraudulent company Schneider Brothers and a fat geriatric named John 'the cuck' Severson. Nemus eventually decided to take legal action (on contingency, mgmt compensation bled company dry). CFO quit or was fired, somehow Murphy managed to stay on. OK CMO, but a poor CEO. Pipeline changed yet again, with glaucoma still being the primary indication. Company went silent for quite a while, one day volume was suspiciously large, lo and behold a 'sweetheart deal' with Emerald was announced shortly thereafter. The Dhillons (of all people lol) took over (great job with Oncosec, Punit!). 2+ years later, still haven't conducted a clinical trial (it's coming!) and share count has exploded. Company has misled shareholders since day 1.
Comment by
Stockqueen77 on Aug 27, 2021 1:37am
This post has been removed in accordance with Community Policy